Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). Patient-reported outcomes. PROGRAMME.and.ABSTRACTS.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

NORML

APRIL 30, 2020

The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”

Chronic Pain 343

Chronic Pain Clinical Trials Data Patients 343

Veriheal

SEPTEMBER 16, 2022

Recent research has found that aerosolized cannabis can provide long-term pain reduction, specifically in patients with neuropathy and other chronic conditions. This device ensures that patients get metered and precise doses of cannabis. Study Assesses Analgesic Potential of Medical Cannabis for Neuropathy Patients.

Patients 120

Patients Chronic Pain Research and Development Treatment 120

CannaMD

OCTOBER 14, 2020

A study published earlier this year reveals a simple but interesting pattern: When patients with ADHD consume more cannabis, they require fewer prescription drugs. According to the study’s research team , patients who consume medical marijuana report a “higher occurrence of stopping all ADHD medications.”

Patients 98

Patients Marijuana Cannabinoids Terpenes 98

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

Project CBD

FEBRUARY 27, 2023

Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. “Available data strongly support the use of cannabinoids in treating fibromyalgia pain” due to “overwhelmingly positive treatment results.”

THC 144

THC CBD Sleep Clinical Trials 144

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

NORML

FEBRUARY 25, 2020

Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Sixty-six patients participated in the study. Half of the participants received dronabinol and the other half did not.

Clinical Trials 229

Clinical Trials THC Consumption Therapy 229

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. There were three Cohorts, with 12 patients in each cohort.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

The Cannigma

JANUARY 16, 2021

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.

Data 100

Data Research and Development Patients Strains 100

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

CannaMD

NOVEMBER 4, 2020

According to a recent study published in the Journal of Headache Pain , across 2,032 patients and 21 illnesses, headache was a symptom treated with cannabis in 24.9% (505) of cases, while 88% (445) of headache patients treated probable migraines with cannabis. 30 percent of migraine patients in the U.S. The results?

Patients 105

Patients Chronic Pain Marijuana Research and Development 105

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).

Clinical Trials 52

Clinical Trials Data Patients THC 52

Veriheal

AUGUST 12, 2021

Patients who suffer from epilepsy , which affects some 3.4 million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). Researchers Analyzed Survey Results from 280 Epilepsy Patients.

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

SpeedWeed

APRIL 10, 2021

Chronic pain patients who used cannabis saw sustained improvement in their condition over time, according to the results of a recently released study. The data revealed a sustained improvement in the participants’ symptoms. The data revealed a sustained improvement in the participants’ symptoms.

Chronic Pain 52

Chronic Pain Patients Treatment Data 52

The Cannigma

NOVEMBER 23, 2021

Listen & Subscribe: Finding the correct dosage and combination of cannabinoid products for medical treatment is almost universally a long and expensive process of trial and error. And for the most part, patients are undertaking this journey alone and often with little guidance.

Data 52

Data Patients Access Wellness and Beauty 52

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. The answer: Maybe!

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

SpeedWeed

MARCH 14, 2021

Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.

Data 52

Data Research and Development Marijuana Collective 52

Veriheal

NOVEMBER 21, 2023

Quemarr Moatamedi School: University of Montana Major/Program: Linguistics and Anthropology Innovation: Emulsion-Based Edibles: Harnessing Anti-Diabetic Cannabinoids in Diabetes Management. Quemarr presents an emulsion-based drug delivery system tailored for cannabinoids and made to tackle America’s diabetes crisis.

Research and Development 106

Research and Development Consumption Education Data 106

MedicalJane

JUNE 12, 2020

Of the 1,276 participants, 524 adult patients and 284 adult caregivers of children or dependent adults, all self-reported using cannabis for medicinal purposes. The control group consisted of 271 adult patients who were considering cannabis use, and 197 adult caregivers who were considering it for a dependent child or adult patient.

Chronic Pain 145

Chronic Pain Epilepsy Patients Medicine 145

Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

United Patients Group

MAY 17, 2023

Introduction Autism spectrum disorder (ASD) is a neurodevelopmental condition that affects communication, social interactions and behaviors. Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention.

Sleep 80

Sleep Cannabinoids Patients CBD 80

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

The Cannigma

FEBRUARY 14, 2021

Fast-forward to 2020, and Smith and two co-founders launched “Tetragram,” a mobile app designed to help medical cannabis patients determine which products — including which strains, formulations, and delivery methods — work best for their ailments or even their recreational use goals. Your goals Why are you using cannabis right now?

Wellness and Beauty 145

Wellness and Beauty Data Terpenes Patients 145

Project CBD

JANUARY 24, 2019

Published in Nature , the study found that just under a third of patients report significant improvements and over half report moderate improvements while using CBD -rich oil derived from cannabis (30% CBD , 1-2% THC ). Endometriosis is a poorly-understood condition causing severe chronic pain and alterations in a woman’s menstrual cycle.

Research and Development 252

Research and Development Chronic Pain Cannabinoids Treatment 252

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. Securities and Exchange Commission (“SEC”) on July 13, 2020. About IGC: India Globalization Capital, Inc.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

SEPTEMBER 29, 2021

The Cannabinoid Institute ?(TCI) With more states legalizing cannabis for medical and recreational use, TCI recognizes the critical role that education plays in reducing patient adverse outcomes and ensuring the safe use of cannabis. TCI was founded by Drs.

Cannabinoids 52

Cannabinoids Education Patients Safety 52

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

The Cannigma

DECEMBER 20, 2021

Recent scientific studies suggest that different cannabinoids and other cannabis-derived molecules (e.g terpenes ) may help treat a number of different skin conditions. Researchers are still in the early stages of learning how exactly cannabinoids affect skin health, but some of the results are compelling.

Terpenes 133

Terpenes Cannabinoids Topical Research and Development 133

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. More Than 1,000 PD Patients Surveyed.

Patients 52

Patients Treatment Therapy Sleep 52

Veriheal

AUGUST 15, 2022

The condition may also occur as a result of poor lifestyle habits, chronic disease, and depression. Data was pulled from 3,922 cannabis self-administration sessions with the help of this application. Minor Cannabinoids vs. CBD and THC. Promising News for Endless Patients. The Releaf App’s Role in the Fatigue Study.

Treatment 96

Treatment Research and Development Sativa Cannabinoids 96

Project CBD

APRIL 5, 2023

In the first part of this series, we reviewed recent research into the role of the CB2 cannabinoid receptor in cancer proliferation. After all, the CNS is the domain of its sibling, the CB1 cannabinoid receptor — the primary target of THC and the mediator of cannabis’ intoxicating effects. That much is clear.

Cannabinoids 175

Cannabinoids CBD Therapy Concentrates 175

Veriheal

MAY 18, 2023

Chronic pain —a condition that affects 50.2 annually — is one of the most common reasons why medical marijuana is sought out by patients in the United States, Canada, and beyond. The list is designed to help patients determine whether or not they are a good candidate for (and would benefit from) a medical marijuana card.

Chronic Pain 98

Chronic Pain Treatment Research and Development Patients 98

Cannabis Law Report

AUGUST 14, 2019

Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Therefore, the growing marijuana market lacks the clinical data needed to help marijuana businesses create new and better products.

Data 45

Data Research and Development Marijuana Collective 45